Phio Pharmaceuticals Corp.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing siRNA therapies derived from RNAi, co-founded by Nobel Prize scientist Craig Mello. Their mission is to create innovative pathways toward a cancer-free future through immuno-oncology solutions.

Products & Services

INTASYL siRNA Technology:A proprietary gene silencing technology that enhances the effectiveness of immune cells in killing cancer cells, with a focus on immuno-oncology.

Pipeline Initiatives:Focused on treatments for cutaneous Squamous Cell Carcinoma (cSCC) and melanoma.

Specialties

siRNA Therapies RNAi-based Treatments Immuno-oncology Cutaneous Squamous Cell Carcinoma (cSCC) Melanoma

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 13400000 MR: - FA: approximately $13.4 million FAN: 13400000	D: 2025-11-03 FD: 2025-11-03	-
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2500000 MR: - FA: approximately $2.5 million FAN: 2500000	D: 2025-07-25 FD: 2025-07-25	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1830000 MR: - FA: 1.83 million FAN: 1830000	D: 2025-01-21 FD: 2025-01-21	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1830000 MR: - FA: $1.83 million FAN: 1830000	D: 2025-01-16 FD: 2025-01-16	1 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2025-01-15 FD: 2025-01-15	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3190000 MR: - FA: $3.19 million FAN: 3190000	D: 2025-01-14 FD: 2025-01-14	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 480000 MR: - FA: $0.48 million FAN: 480000	D: 2024-12-23 FD: 2024-12-23	-
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1150000 MR: - FA: 1.15 million FAN: 1150000	D: 2024-12-19 FD: 2024-12-19	1 investors
9	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3100000 MR: - FA: 3.1 million FAN: 3100000	D: 2024-07-12 FD: 2024-07-12	1 investors
10	RT: Equity T: - FT: Equity	A: 621000 MR: - FA: up to $621,000 FAN: 621000	D: 2024-05-17 FD: 2024-05-17	1 investors
11	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2800000 MR: - FA: $2.8 million FAN: 2800000	D: 2023-12-07 FD: 2023-12-07	1 investors
12	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 4000000 MR: - FA: 4.0 million FAN: 4000000	D: 2023-06-02 FD: 2023-06-02	1 investors
13	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 4000000 MR: - FA: approximately $4 million FAN: 4000000	D: 2023-05-31 FD: 2023-05-31	1 investors
14	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: 2.0 million FAN: 2000000	D: 2023-04-20 FD: 2023-04-20	-
15	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-04-18 FD: 2023-04-18	1 investors

Warrant Exercise Latest

2025-11-03

$13.4M

Warrant Exercise 2025-07-25

$2.5M

Registered Direct Offering 2025-01-21

$1.8M

View 14 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert Bitterman

President & Chief Executive Officer

L

Lisa Carson

VP of Finance and Administration

L

Linda Mahoney

SVP of Development

J

Jennifer Phillips

VP of Regulatory & Corporate Affairs

R

Robert M. Infarinato

VP Strategic Development

View 2 more team members with Pro

Unlock Full Team Directory

Recent News